Dealmakers newsletter: November 2008
Welcome to November's edition of the Dealmakers newsletter from CurrentPartnering.
Sponsored by: Intralinks | EuroPLX | DMS Data Systems
If not already signed up to receive our newsletters, do so here.
In this issue:
- Editor's corner
- New partnering reports
- Partnering roundup
- Networks update - discussion forums activated
- In the news - November 2008
- New best practice articles
- Forthcoming events
- Scorecards - newly updated with latest deals
- People on the move
- Partnering resources: Online partnering
- Glossary of partnering terms
The November issue of Dealmakers is sponsored by:
Datamonitor's new report: M&A trends in Pharma
M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable as desired. Current trends show the mega-mergers of the past are now a long gone strategy, as now companies are seeking to buy smaller companies for a smaller fee.
For further details visit M&A trends in Pharma
EDITOR'S CORNER
Times continue to be difficult for the biopharma sector, however creative partnering provides opportunity for smaller companies to obtain well needed finances and larger companies to access or acquire new products and technologies.
In this issue of Dealmaker's newsletter we feature a series of reports that outline the strategies and best practise to survive the credit squeeze, whether it be M&A or creative alliances.
You can also view the leading deals so far this year in our updated Scorecards.
Finally this month, our timely roundup of partnering related articles across the web continues to provide you with access the leading thinkers in the partnering space. Each article focuses on a topic of particular interest to the biopharma industry including financing, IP, M&A, partnering.
Until next time - happy dealmaking!
- Steve Poile
NEW PARTNERING REPORTS
With hard times upon us, the need for creative dealmaking is more pressing than ever. Fortunately, the strategies and best practices for creative M&A and alliances is available at your fingertips through the numerous recent reports published by Business Insights, CurrentPartnering, CuttingEdge, and Datamonitor.
The following is just a selection of the reports recently published and available now.
Biotech M&A Strategies: Deal assessments, trends and future prospects
Identify the latest trends in M&A activity with this report’s detailed analysis of deal values and volumes over the 2003-2008 period and a geographical breakdown of target and acquirer locations
Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships
Provides a detailed examination of the current alliance landscape and analyses the underlying factors that can determine their success or failure
Successful Pharmabiotech Alliance Strategies
Pharmaceutical Alliance Management
Provides practical and proven solutions to the most common challenges facing collaborations among pharma and biotech companies
Business Development and Pharmaceutical Alliance Management
Business Development: Accelerating the Deal
Reveals how pharmaceutical and biotechnology companies of all sizes approach the deal-making process: from business development strategy, structure and funding to opportunity identification, due diligence and deal negotiation
Business Development: Accelerating the Deal
Partnering with Bigpharma
The report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies Partnering with Bigpharma
Individual Partnering Guides for each of the top 50 bigpharma companies are also available
Pfizer - GlaxoSmithKline - Sanofi-Aventis - Novartis - AstraZeneca - Johnson & Johnson - Merck - Roche - Wyeth - Eli Lilly - Bristol-Myers Squibb - Mayer - Abbott - Amgen - Boehringer-Ingelheim - Schering-Plough - Takeda - Genentech - Teva - Novo Nordisk - Astellas - Daiichi Sankyo - Merck KGaA - Eisai - Otsuka - Servier - UCB - Baxter - Nycomed - Solvay - Gilead - Genzyme - Forest - Menarini - Allergan - Mitsubishi Tanabe - Chugai - Procter & Gamble - Ratiopharm - CSL - Barr - Alcon - Mundipharma - Shire - Biogen Idec - Stada - King - Lundbeck - Activis - Watson
Full list of top 50 companies covered
If you are looking for development stage specific intelligence, the following will be of interest:
Discovery Stage Partnering Agreements in Biopharma
The Discovery Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies Discovery Stage Partnering Agreements in Biopharma report.
Pre-clinical Stage Partnering Agreements in Biopharma
The Pre-clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the pre-clinical stage partnering agreements entered into by the worlds leading biopharma companies Pre-clinical Stage Partnering Agreements in Biopharma report.
Clinical Stage Partnering Agreements in Biopharma
The Clinical Stage Partnering Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the clinical stage partnering agreements entered into by the worlds leading biopharma companies Clinical Stage Partnering Agreements in Biopharma report.
If you are looking for deal-type specific intelligence then the following are available:
Co-promotion & Co-marketing Agreements in Biopharma
The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies Co-promotion & Co-marketing Agreements in Biopharma
Also:
- Manufacturing and Supply Agreements in Biopharma
- Distribution Agreements in Biopharma
- Bigpharma Partnering Agreements
- Merger and Acquisition Agreements in Biopharma
- Practical Guide to Finding Partners in Biopharma
PARTNERING ROUNDUP
The following are a list of articles of interest to business developers - updated monthly in this newsletter links working at time of publication
We need super-funds says entrepreneur
Top 10 Intellectual Property And Regulatory Legal Issues For Biotech Start-Ups
Big Pharma Embraces the Contentious Cancer Business
Credit crunch presents buying opportunities for big pharma
Firm Size and the Use of Intellectual Property Rights
The Basics of Mergers & Acquisitions Due Diligence
The Good News for Biotech: New Regulation Opens a New Path to Profitability
A silver lining for pharmaceuticals
Deal Between Big Pharma to Brighten the Gloom?
Collapsing Credit Markets to Fuel More Partnering?
Four New Pharmaceutical Chief Executives Speak Out
NETWORKS - discussion forums activated at LinkedIn
We are pleased to announce that our discussion forums have now been activated at LinkedIn, proviing you the opportunity to actively network the group with your questions.
Networks facilitates the connecting of business developers in biopharma through the use of social networkings tools - including LinkedIn, Plaxo, Facebook, Twitter and GoogleMaps.
To join or participate in CurrentPartnering's Network tools, just click on the link below for further details Networks - join now!
IN THE NEWS
The latest partnering developments - November 2008:
November has been a slow month for partnership and M&A accouncements, here are a few that did make it:
- TorreyPines sells Alzheimer's disease genetics program to Eisai
- XOMA restructures drug development collaboration with Novartis Vaccines & Diagnostics
- ArQule and Daiichi Sankyo enter strategic R&D partnership to progress compounds targeting cancer
- WuXi PharmaTech signs new collaboration with Pfizer
- Winston Laboratories announces licensing agreement with Sanofi-Aventis in Canada
- Cabernet and Eli Lilly form pharmacogenetics alliance to help deliver tailored therapeutics to patients
NEW BEST PRACTICE ARTICLES
Are Economics of Partnering Events Measurable? - Part 2
The only alternative to a partnering conference is visiting the companies or being visited
Opportunity knocks for big pharmaceutical companies in the credit crunch
Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich
FORTHCOMING EVENTS
Here is our suggested partnering events for the fall of 2008 and start of 2009.
BioEurope 2008
Mannheim, Germany - November 17-19, 2008
The 14th annual BIO-Europe event is the world’s largest dedicated biotechnology partnering conference BioEurope 2008
Pharma Business Strategies for Biomarkers
San Francisco, CA, USA, December 11-12, 2008
Top business development executives talk about how biomarkers are driving value in today’s dealmaking environment Pharma Business Strategies for Biomarkers
13th Annual Drug Delivery Partnerships
Las Vegas, NV, USA - January 21-23, 2009
13th Annual Drug Delivery Partnerships
EuroPLX 39 Lisbon
Cascais (near Lisbon), Portugal - March 2-3, 2009
SCORECARDS
Our scorecards have been updated with the latest deals to break into our most valuable deal rankings.
In addition, we have updated our top 25 bigpharma partnering activity scorecard for deals up to end October 2008.
- Partnering Top 20 - 2008
- Partnering Top 20 - 2007
- Partnering since 2000
- M&A Top 20 - 2008
- M&A Top 20 - 2007
- M&A since 2000
- Bigpharma Top 25 partnering - 2008
PEOPLE ON THE MOVE
The following people have been reported on the move during the weeks of October/November 2008:
Eric Nelson, Ralph Johnston, Adelene Perkins, Linda Hogan, John MacInnis, Guy Van Meter, Harold Strandquist, Mark Sutherland to name just a few
read more about the latest people on the move
If you have news about a business development executive who is on the move - let us know
PARTNERING RESOURCES: ONLINE PARTNERING
Numerous online websites exist to support finding and securing partners, whether you are a corporation of academic organization - Online partnering
GLOSSARY: UPDATED PARTNERING TERMS
The most recent addition is SPC or Supplementary Protection Certificate - a concession granted to pharma to extend protection under a patent more details
Full Glossary can be accessed here
Do you have specific glossary terms that you would like to see in our website? Give us your ideas here
CurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers
- Reports
- Articles
- In the news
- Networks
- Scorecard
- Events
- On the move
- Careers
- Glossary
- Resources
- Advisers
Advertizing and sponsorship
CurrentPartnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.
or contact us to discuss your requirements.
Steve Poile, Editor
Web: http://www.CurrentPartnering.com
Mail: CurrentPartnering, Allanmere House, 6 Hobgate, York, YO24 4HF, United Kingdom
Tel: +44 7896 656732
Fax: +44 8703 305993
Scorecard Index
Deal term reports
The information you provide is excellent and we look forward to doing more business with you in the future
...You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date...
CurrentPartnering Reports
The latest reports on best practise for dealmakers available from CurrentPartnering
Quick links
Term of the week...
Heads of agreement A pre-agreed document that outlines the key elements and structure of the planned deal.